Evidence map›Paper›PMID 32238509›Full record

SynthesisNeurology2020

Meta-analysis of drug efficacy in adult vs pediatric trials of patients with PGTC seizures.

Douglas R Nordli, Emilia Bagiella, Alexis Arzimanoglou, Jinping Wang, Dinesh Kumar, Antonio Laurenza, Jacqueline French

Open access · bronzeAbstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Neurology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Douglas R NordliFrom the University of Chicago (D.R.N.), IL; Mount Sinai School of Medicine (E.B.), New York, NY; Department of Pediatric Clinical Epileptology, Sleep Disorders and Functional Neurology (A.A.), University Hospitals of Lyon (HCL), Member of the European Reference Network EpiCARE, Lyon, France; Paediatric Epilepsy Unit (A.A.), Hospital Sant Joan de Déu, Member of the European Reference Network EpiCARE and Universitat de Barcelona, Spain; Eisai Inc. (J.W., D.K., A.L.), Woodcliff Lake, NJ; and NYU Comprehensive Epilepsy Center (J.F.), New York, NY. dnordli@peds.bsd.uchicago.edu.
Emilia BagiellaFrom the University of Chicago (D.R.N.), IL; Mount Sinai School of Medicine (E.B.), New York, NY; Department of Pediatric Clinical Epileptology, Sleep Disorders and Functional Neurology (A.A.), University Hospitals of Lyon (HCL), Member of the European Reference Network EpiCARE, Lyon, France; Paediatric Epilepsy Unit (A.A.), Hospital Sant Joan de Déu, Member of the European Reference Network EpiCARE and Universitat de Barcelona, Spain; Eisai Inc. (J.W., D.K., A.L.), Woodcliff Lake, NJ; and NYU Comprehensive Epilepsy Center (J.F.), New York, NY.
Alexis ArzimanoglouFrom the University of Chicago (D.R.N.), IL; Mount Sinai School of Medicine (E.B.), New York, NY; Department of Pediatric Clinical Epileptology, Sleep Disorders and Functional Neurology (A.A.), University Hospitals of Lyon (HCL), Member of the European Reference Network EpiCARE, Lyon, France; Paediatric Epilepsy Unit (A.A.), Hospital Sant Joan de Déu, Member of the European Reference Network EpiCARE and Universitat de Barcelona, Spain; Eisai Inc. (J.W., D.K., A.L.), Woodcliff Lake, NJ; and NYU Comprehensive Epilepsy Center (J.F.), New York, NY.
Jinping WangFrom the University of Chicago (D.R.N.), IL; Mount Sinai School of Medicine (E.B.), New York, NY; Department of Pediatric Clinical Epileptology, Sleep Disorders and Functional Neurology (A.A.), University Hospitals of Lyon (HCL), Member of the European Reference Network EpiCARE, Lyon, France; Paediatric Epilepsy Unit (A.A.), Hospital Sant Joan de Déu, Member of the European Reference Network EpiCARE and Universitat de Barcelona, Spain; Eisai Inc. (J.W., D.K., A.L.), Woodcliff Lake, NJ; and NYU Comprehensive Epilepsy Center (J.F.), New York, NY.
Dinesh KumarFrom the University of Chicago (D.R.N.), IL; Mount Sinai School of Medicine (E.B.), New York, NY; Department of Pediatric Clinical Epileptology, Sleep Disorders and Functional Neurology (A.A.), University Hospitals of Lyon (HCL), Member of the European Reference Network EpiCARE, Lyon, France; Paediatric Epilepsy Unit (A.A.), Hospital Sant Joan de Déu, Member of the European Reference Network EpiCARE and Universitat de Barcelona, Spain; Eisai Inc. (J.W., D.K., A.L.), Woodcliff Lake, NJ; and NYU Comprehensive Epilepsy Center (J.F.), New York, NY.
Antonio LaurenzaFrom the University of Chicago (D.R.N.), IL; Mount Sinai School of Medicine (E.B.), New York, NY; Department of Pediatric Clinical Epileptology, Sleep Disorders and Functional Neurology (A.A.), University Hospitals of Lyon (HCL), Member of the European Reference Network EpiCARE, Lyon, France; Paediatric Epilepsy Unit (A.A.), Hospital Sant Joan de Déu, Member of the European Reference Network EpiCARE and Universitat de Barcelona, Spain; Eisai Inc. (J.W., D.K., A.L.), Woodcliff Lake, NJ; and NYU Comprehensive Epilepsy Center (J.F.), New York, NY.
Jacqueline FrenchFrom the University of Chicago (D.R.N.), IL; Mount Sinai School of Medicine (E.B.), New York, NY; Department of Pediatric Clinical Epileptology, Sleep Disorders and Functional Neurology (A.A.), University Hospitals of Lyon (HCL), Member of the European Reference Network EpiCARE, Lyon, France; Paediatric Epilepsy Unit (A.A.), Hospital Sant Joan de Déu, Member of the European Reference Network EpiCARE and Universitat de Barcelona, Spain; Eisai Inc. (J.W., D.K., A.L.), Woodcliff Lake, NJ; and NYU Comprehensive Epilepsy Center (J.F.), New York, NY.
University of Chicago · USEisai (United States) · USIcahn School of Medicine at Mount Sinai · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveA meta-analysis of published studies was performed to determine whether the efficacy of antiseizure drugs in adults with primary generalized tonic-clonic seizures (PGTCS) is comparable with that in the pediatric population (2-12 years of age).

methodsElectronic searches were conducted in EMBASE, Medline, and the Cochrane Central Register of Controlled Trials for clinical trials of PGTCS in adults and children 2-12 years of age. Neurologists used standardized search and study evaluations to select eligible trials. Median percent reduction in seizure frequency from baseline and ≥50% responder rates were used to compare drug efficacy in adults and children.

resultsAmong 7 adjunctive-therapy PGTCS trials in adults and children (2-12 years of age) that met evaluation criteria, effect sizes were consistent between adults and children for lamotrigine and topiramate. The baseline-subtracted median percent seizure reduction in seizure frequency ranged from 50.0% to 79.7% in children and 57.0% to 64.0% in adults. The ≥50% responder rate was similar between children and adults in a topiramate study (50% in children compared with 58% in adults).

conclusionsThis meta-analysis supports the use of drug response from antiseizure drug clinical trials for PGTCS in adults to predict comparable treatment response in children 2-12 years of age with PGTCS.

Indexed as

AdolescentAdultAnticonvulsantsChildChild, PreschoolEpilepsy, Tonic-ClonicFemaleHumansMaleAnticonvulsants

Identifiers

PMID32238509
PMCPMC7274844
OpenAlexW3014334437

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.